Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mazen Elyan

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
The American Journal of Medicine|July 1, 2008
Why does C-reactive protein predict coronary events?Irving Kushner, Mazen Elyan
Clinical Rheumatology|March 26, 2009
The effectiveness and safety of mycophenolate mofetil in lupus nephritisMazen Elyan, Stanley Ballou
Current Rheumatology Reports|July 25, 2006
The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitisMazen Elyan, Muhammad Asim Khan
The Journal of Rheumatology. Supplement|October 17, 2006
Diagnosing ankylosing spondylitisMazen Elyan, Muhammad Asim Khan
Current Opinion in Rheumatology|April 5, 2008
Does physical therapy still have a place in the treatment of ankylosing spondylitis?Mazen Elyan, Muhammad Asim Khan
Current Rheumatology Reports|October 5, 2007
Sulfasalazine in undifferentiated spondyloarthropathiesMazen Elyan, Muhammad Asim Khan
Current Rheumatology Reports|October 5, 2007
Is low-dose infliximab every 8 weeks effective in treating ankylosing spondylitis?Mazen Elyan, Muhammad Asim Khan
Current Rheumatology Reports|October 5, 2007
Another look at low-dose infliximab in treating ankylosing spondylitisMazen Elyan, Muhammad Asim Khan
Clinical Rheumatology|May 24, 2007
Pericarditis: a rare complication of methotrexate therapyTayyab Mohyuddin, Mazen Elyan, Irving Kushner
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 20, 2017
A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic ArthritisJawad Bilal, Irbaz Bin Riaz, Muhammad Umar Kamal, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
The American Journal of Medicine|July 1, 2008
Why does C-reactive protein predict coronary events?Irving Kushner, Mazen Elyan
Clinical Rheumatology|March 26, 2009
The effectiveness and safety of mycophenolate mofetil in lupus nephritisMazen Elyan, Stanley Ballou
Current Rheumatology Reports|July 25, 2006
The role of nonsteroidal anti-inflammatory medications and exercise in the treatment of ankylosing spondylitisMazen Elyan, Muhammad Asim Khan
The Journal of Rheumatology. Supplement|October 17, 2006
Diagnosing ankylosing spondylitisMazen Elyan, Muhammad Asim Khan
Current Opinion in Rheumatology|April 5, 2008
Does physical therapy still have a place in the treatment of ankylosing spondylitis?Mazen Elyan, Muhammad Asim Khan
Current Rheumatology Reports|October 5, 2007
Sulfasalazine in undifferentiated spondyloarthropathiesMazen Elyan, Muhammad Asim Khan
Current Rheumatology Reports|October 5, 2007
Is low-dose infliximab every 8 weeks effective in treating ankylosing spondylitis?Mazen Elyan, Muhammad Asim Khan
Current Rheumatology Reports|October 5, 2007
Another look at low-dose infliximab in treating ankylosing spondylitisMazen Elyan, Muhammad Asim Khan
Clinical Rheumatology|May 24, 2007
Pericarditis: a rare complication of methotrexate therapyTayyab Mohyuddin, Mazen Elyan, Irving Kushner
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|September 20, 2017
A Systematic Review and Meta-analysis of Efficacy and Safety of Novel Interleukin Inhibitors in the Management of Psoriatic ArthritisJawad Bilal, Irbaz Bin Riaz, Muhammad Umar Kamal, et al.
Pageof 1